FY2025 Earnings Forecast for Annexon Issued By HC Wainwright

Annexon, Inc. (NASDAQ:ANNX) – Stock analysts at HC Wainwright reduced their FY2025 earnings estimates for Annexon in a research report issued on Wednesday, November 12th. HC Wainwright analyst A. Ghosh now forecasts that the company will post earnings of ($1.42) per share for the year, down from their prior forecast of ($1.34). HC Wainwright has a “Buy” rating and a $14.00 price target on the stock. The consensus estimate for Annexon’s current full-year earnings is ($0.96) per share. HC Wainwright also issued estimates for Annexon’s Q4 2025 earnings at ($0.36) EPS, Q1 2026 earnings at ($0.36) EPS, Q2 2026 earnings at ($0.36) EPS, Q3 2026 earnings at ($0.35) EPS, Q4 2026 earnings at ($0.35) EPS, FY2026 earnings at ($1.43) EPS, FY2027 earnings at ($1.09) EPS, FY2028 earnings at ($0.62) EPS and FY2029 earnings at ($0.04) EPS.

Annexon (NASDAQ:ANNX) last released its quarterly earnings data on Monday, November 10th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.03).

Several other equities analysts have also weighed in on the stock. Zacks Research raised shares of Annexon from a “strong sell” rating to a “hold” rating in a report on Monday, August 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Annexon in a research report on Wednesday, October 8th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $12.50.

Annexon Price Performance

ANNX stock traded up $0.09 during trading on Friday, hitting $2.77. 418,013 shares of the company traded hands, compared to its average volume of 1,659,424. Annexon has a 1 year low of $1.28 and a 1 year high of $6.49. The company has a market cap of $303.84 million, a PE ratio of -2.15 and a beta of 1.28. The stock’s 50-day simple moving average is $2.94 and its 200 day simple moving average is $2.51.

Hedge Funds Weigh In On Annexon

Hedge funds have recently made changes to their positions in the company. Nuveen LLC purchased a new position in Annexon in the 1st quarter valued at $670,000. J. Safra Sarasin Holding AG raised its position in shares of Annexon by 49.9% in the second quarter. J. Safra Sarasin Holding AG now owns 381,441 shares of the company’s stock valued at $915,000 after buying an additional 126,903 shares during the last quarter. Wellington Management Group LLP lifted its stake in shares of Annexon by 32.9% in the first quarter. Wellington Management Group LLP now owns 356,480 shares of the company’s stock worth $688,000 after buying an additional 88,314 shares in the last quarter. XTX Topco Ltd boosted its position in Annexon by 65.4% during the first quarter. XTX Topco Ltd now owns 58,130 shares of the company’s stock worth $112,000 after acquiring an additional 22,979 shares during the last quarter. Finally, Matauro LLC purchased a new stake in Annexon during the 2nd quarter valued at about $27,000.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.